Voyager Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Voyager Therapeutics's estimated annual revenue is currently $15.9M per year.
- Voyager Therapeutics received $75.0M in venture funding in November 2017.
- Voyager Therapeutics's estimated revenue per employee is $90,227
- Voyager Therapeutics's total funding is $135M.
- Voyager Therapeutics's current valuation is $108.2M. (January 2022)
Employee Data
- Voyager Therapeutics has 176 Employees.
- Voyager Therapeutics grew their employee count by 26% last year.
Voyager Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $4.2M | 27 | 35% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $1.4M | 9 | 29% | N/A | N/A |
#6 | $235M | 255 | -31% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.3M | 34 | 0% | N/A | N/A |
#10 | $1.9M | 12 | -8% | N/A | N/A |
What Is Voyager Therapeutics?
Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson's disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Alzheimer's Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data. Contact: Voyager Therapeutics 75 Sidney St. Cambridge, MA 02139 info@voyagertherapeutics.com 857-259-5340
keywords:Biotechnology,Healthcare,Pharmaceuticals$135M
Total Funding
176
Number of Employees
$15.9M
Revenue (est)
26%
Employee Growth %
$108.2M
Valuation
N/A
Accelerator
Voyager Therapeutics News
Read Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Buy at StockNews.com at Defense World.
By Josh Beckerman. Voyager Therapeutics Inc. shares were recently down 33% to $6.75 and were briefly paused due to volatility more than an...
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate...
With its lead gene therapy programs stalled by a series of setbacks, Voyager Therapeutics has been talking for months about refocusing its business on internal technology that finds capsids—the protein shells that envelope a gene therapy and deliver it into a target cell. That strategy is starti ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $34.1M | 176 | 15% | $351M |
#2 | $56.1M | 176 | 5% | N/A |
#3 | $34.1M | 176 | -26% | $367M |
#4 | $28.1M | 176 | 13% | N/A |
#5 | $52.6M | 177 | N/A | N/A |
Voyager Therapeutics Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2014-02-13 | $45.0M | A | Third Rock Ventures | Article |
2015-02-12 | $30.0M | Undisclosed | Genzyme | Article |
2015-04-14 | $60.0M | B | Brookside Capital | Article |
2017-11-08 | $75.0M | Undisclosed | Morgan Stanley | Article |
Voyager Therapeutics Executives
Name | Title |
---|---|
Michelle Smith | Chief Human Resources Officer |
Alfred Sandrock | Chief Executive Officer |
Peter Pfreundschuh | Chief Financial Officer |
Todd Carter | Chief Scientific Officer |
Allen Nunnally | Chief Business Officer |
Scott Townsend | Chief Corporate Counsel and Senior Vice President of Legal Affairs |
Rachael DiMestico | Executive Assistant to Chief Medical Officer and SVP of Neuroscience |
Michelle Quinn Smith | Chief Human Resources Officer |
Steven Paul | CEO and Chairman of the Board |
Robin Swartz | Chief Operating Officer |
Andre Turenne | President & CEO |
Glenn Pierce | Interim Chief Scientific Officer |
Trista Morrison | SVP of Corporate Affairs |
Chad Holland | Vice President, Program, Portfolio & Alliance Management |
Christina Gamba-Vitalo | Vice President Toxicology and DMPK |
Holger Patzke | Vice President, Neuroscience and Head of Translational Biology |
Scott Townsend | Chief Corporate Counsel and Senior Vice President of Legal Affairs |
Charlie Harper | Vice President CMC, Ext Manufacturing and Supply |
Jennifer Hunt | Senior Vice President, Development Operations and Regulatory Affairs |
Rachael DiMestico | Executive Assistant to Chief Medical Officer and SVP of Neuroscience |
Petra Sansom | Vice President, Alliance Management |
Brandi Simpson | Vice President, Business and Corporate Development |
Julie Burek | Vice President, Finance |
Kelly Bales | SVP Neuroscience |
Andre Turenne | President & CEO |
Juliana Muscat | Vice President of Quality |
Claire Sampson | VP Global Regulatory Affairs |
Jay Hou | Vice President, Vector Engineering |
Holger Patzke | Vice President, Neuroscience and Head of Translational Biology |